CNS & Neurological Disorders - Drug Targets

Journal Impact Factor: 3.0
Scopus Cite Score: 5.5

Indexed in: Scopus, SCI Expanded, MEDLINE/PubMed

View All
Aims and Scope:
CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. CNS & Neurological Disorders - Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of CNS & neurological drug targets. The journal also accepts for publication original research articles, letters, reviews and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.
Read more...

Editor-in-Chief:

  • Edoardo Spina Department of Clinical and Experimental Medicine
    University of Messina
    Messina
    Italy

ISSN: 1871-5273 (Print)

eISSN: 1996-3181 (Online)

Special Issues With Active Call for Papers

Submission closes on: Mar 14, 2026
Innovative Therapeutics in Demyelinating CNS- Disorders: Immune Modulation, Antibody Therapy, Kinase Inhibition and Remyeliation Strategies

Demyelinating disorders, particularly multiple sclerosis represent chronic disease characterized by inflammation, demyelination, and neurodegeneration within the central nervous system. This thematic issue will present a comprehensive overview of novel therapeutic advances targeting these processes. In addition to dissecting the roles of innate versus adaptive immunity, antibody therapies, and tyrosine kinase inhibitors, the issue emphasizes emerging remyelination strategies. Recent data—including early intervention with anti-CD20 treatments - underscore the benefits of a “hit hard and early” approach,... see more